[Influence of angiotensin I converting enzyme inhibitors on selected parameters of zinc metabolism].

What Was Tested

The paper reports a study of Angiotensin-Converting Enzyme Inhibitors and Captopril, published as a randomized controlled trial.

The aim of the study was to assess the influence of angiotensin converting enzyme inhibitors (ACEI) on zinc metabolism.

Who Took Part

PubMed indexes the participants as adults and middle-aged adults, both men and women.

Thirty one patients (pts) with essential hypertension (EH) were divided into two groups: 1. 16 pts. 6 females (F) and 10 males (M) (age 46.5 +/- 7) who were treated with benazepril (nonsulphydryl ACEI). 2. 15 pts, 6F and 9M (age 45.9 +/- 10.7) receiving captopril (sulphdryl ACEI).

Erythrocyte (ZnE) and serum (ZnS) zinc as well as 24 hour urinary zinc excretion (ZnU) and glomerular filtration rate were assessed before starting treatment and after 4 and 8 weeks of ACEI therapy.

How the Study Was Run

The design is described as randomized and double-blind.

Because people in this Angiotensin-Converting Enzyme Inhibitors study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Angiotensin-Converting Enzyme Inhibitors.

What Was Measured

The subject headings attached to it are Angiotensin-Converting Enzyme Inhibitors, Benzazepines, Captopril, Hypertension and Zinc.

What This Means in Plain Language

The paper is a randomized and double-blind study of Angiotensin-Converting Enzyme Inhibitors and Captopril.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 1996 (Polskie Archiwum Medycyny Wewnetrznej), a journal based in Poland.

More context: all human trials.